Dietary isoflavones act on bone marrow osteoprogenitor cells and stimulate ovary development before influencing bone mass in pre-pubertal piglets

Journal of Cellular Physiology

Volumn 212, Issue 1, 2007, Pages 51-59

  De Wilde, Anne ^a   Rassi, Claudia Maria ^a   Cournot, Giulia ^b   Colin, Colette ^a   Lacroix, Herminie C ^a   Chaumaz, Gilles ^a   Coxam, Veronique ^b   Bennetau Pelissero, Catherine ^c   Pointillart, Alain ^a   Lieberherr, Michele ^a,b  

^a INRA   (France)

^b CNRS   (France)

^c UMRS ENITAB   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; CASPASE 3; DAIDZEIN; EQUOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENISTEIN; ISOFLAVONE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PHYTOESTROGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE MARROW; BONE MASS; BONE STRENGTH; CONTROLLED STUDY; DIETARY INTAKE; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMERUS; METACARPAL BONE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OVARY DEVELOPMENT; OVARY FOLLICLE; PREPUBERTY; PRIORITY JOURNAL; SOYBEAN; STEM CELL; STROMA CELL; SWINE; TIBIA; UTERUS WEIGHT; WESTERN BLOTTING;

ALKALINE PHOSPHATASE; ANIMALS; BONE DENSITY; BONE MARROW CELLS; DIET; FEMALE; ISOFLAVONES; OSTEOBLASTS; OSTEOCALCIN; OSTEOCLASTS; OVARY; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, ESTROGEN; SEXUAL MATURATION; STEM CELLS; SWINE;

GLYCINE MAX; RATTUS; SUIDAE;

EID: 34249874639     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21002     Document Type: Article

References (88)

1. Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T. 2000. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr 72:844-852.
2. An J, Tzagarakis-Foster C, Scharschmidt TC, Lomri N, Leitman DC. 2001. Estrogen receptor β-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem 276:17808-17814.
3. Anderson JB, Chen XW, Garner SC. 2000. Effects of genistein on MC3T36EI, an osteoblast cell line, in relation to expression of estrogen receptors α and β and during cell differentiation. J Nutr 130:666S-667S.
4. Anderson JJ, Chen X, Boass A, Symons M, Kohlmeier M, Renner JB, Garner SC. 2002. Soy isoflavones: No effect on bone mineral density in healthy, menstruating young adult women after one year. J Am Coll Nutr 21:388-393.
5. Arjmandi BH, Alekel L, Hollis BW, Amin D, Stacewicz-sapuntzakis M, Guo P, Kukrela SC. 1996. Dietary soybean protein prevents bone loss in ovarlectomized rat model of osteoporosis. J Nutr 126:161-167.
6. Aubin JE. 1998. Advances in the osteoblast lineage. Biochem Cell Biol 76:899-910.
7. Bahr JM, Nakal M, Rivera A, Walsh J, Evans GL, Lotinun S, Turner RT, Black M, Jeffery EH. 2005. Dietary soy protein and isoflavones: Minimal beneficial effects on bone and no effect on reproductive tract of sexually mature ovarlectomized Sprague-dawley rats. Menopause 12:165-173.
8. Bennetau-Pelissero C, Le Houerou C, Lamothe V, Le Menn F, Babin P, Bennetau B. 2000. Synthesis of haptens and conjugates for ELISAs of phytoestrogens. Development of the immunological tests. J Agric Food Chem 48:305-311.
9. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
10. Branca F. 2003. Dietary phyto-estrogens and bone health. Proc Nutr Soc 62:877-887.
11. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL. 1999. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527-538.
12. Cassidy A, Albertazzi P, Lise Nielsen I, Hall W, Williamson G, Tetens I, Atkins S, Cross H, Manlos Y, Wolk A, Steiner C, Branca F. 2006. Critical review of health effects of soyabean phyto-oestrogens in post-menopausal women. Proc Nutr Soc 65:76-92.
13. Chen WY, Manson JE, Hankinson SE, Rosner B, Holmes MD, Willett WC, Colditz GA. 2006. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 166:1027-1032.
14. Chiang CH, Cheng KW, Igarashi S, Nathwani PS, Leung PC. 2000. Hormonal regulation of estrogen receptor alpha and beta gene expression in human granulosa-luteal cells in vitro. J Clin Endocr Metab 85:3828-3839.
15. Clarkson T, Anthony MS, Williams JK, Honore EK, Cline JM. 1998. The potential of soybean phytoestrogens for postmenopausal hormone replacement therapy. Proc Soc Exp Biol Med 217:365-368.
16. Colditz GA. 1999. Hormones and breast cancer. Evidence and implications for consideration of risks and benefits of hormone replacement therapy. J Womens Health 8:347-357.
17. Cotroneo MS, Wang J, Eltoum I-EA, Lamartiniere CA. 2001. Sex steroid receptor regulation by genistein in the prepubertal rat uterus. Mol Cell Endocrinol 173:135-145.
18. Davis SR, Dalais FS, Simpson ER, Murkies AL. 1999. Phytoestrogens in health and disease. Recent Prog Horm Res 54:185-210.
19. De Wilde A, Lieberherr M, Colin C, Pointillart A. 2004. A low dose of daldzein acts as an ERβ-selective agonist in trabecular osteoblasts in young female piglets. J Cell Physiol 200:253-262.
20. Denis I, Cournot G, Lacroix H, Colin C, Zerath E, Pointillart A. 2000. In vivo bone metabolism and ex vivo bone marrow osteoprogenitors in vitamin D-deprived pigs. Bone 26:491-498.
21. Draper CR, Edel MJ, Dick IM, Randall AG, Martin GB, Prince RL. 1997. Phytoestrogens reduce bone loss and bone resorption in oophorectomized rats. J Nutr 127:1795-1799.
22. Duncan AM, Phippa WR, Kurzer MS. 2003. Phyto-estrogens. Best Prect Res Clin Endocrinol Metab 17:253-271.
23. Fantl P, Monier-Faugere MC, Geng Z, Schmidt J, Morris PE, Cohen D, Malluche HH. 1998. The Phyoestrogen genistein reduces bone loss in short-term ovarectomized rat. Osteoporosis Int 8:247-281.
24. Fonseca D, Ward WE. 2004. Daldzein together with high calcium preserve bone mass and biochemical strength at multiple sites in ovariectomized mice. Bone 35:489-497.
25. Galvin RJS, Bryan P, Horn JW, Rippy MK, Thomas JE. 1996. Development and characterization of a porcine model to study osteoclast differentiation and activity. Bone 19:271-279.
26. 2+ signaling. Biol Pharm Bull 22:805-809.
27. Giampietro PG, Bruno G, Furcolo G, Casati A, Brunetti E, Spadoni GL, Galli E. 2004. Soy protein formulas in children: No hormonal effects in long-term feeding. J Pediatr Endocrinol Metab 17:191-196.
28. Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL. 2000. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 141:4768-4776.
29. Gray CA, Bartol FF, Tarleton BJ, Wiley AA, Johnson GA, Baser FW, Spencer TE. 2001. Developmental biology of uterine glands. Biol Reprod 65:1311-1323.
30. Heaney RP, Abrams S, Dawson-Hughes B, Looker A, Marcus R, Matkovic V, Weaver C. 2000. Peak bone mass. Osteoporos Int 11:985-1009.
31. Hillman LS. 1998. Bone mineral concent in term infants fed human milk, cow milk-based formula, or soy-based formula. J Pediatr 113:208-212.
32. Ikeda Y, Iki M, Morita A, Kajita E, Kagamimori S, Kagawa Y, Yoneshima H. 2006. Intake of fermented soybeans, natto, is associated with reduced bone loss in postmenopausal women: Japanese Population-Based Osteoporosis (JPOS) Study. J Nutr 136:1323-1328.
33. Ishimi Y, Miyaura C, Ohmura M, Onoe Y. 1999. Selective effects of genistein, a soybean isoflavone, on B-lymphopolesis and bone loss caused by estrogen deficieny. Endocrinology 140:1893-1900.
34. Iwaniec UT, Crenshaw TD. 1998. Distribution of mineralization indices of modelling and remodelling over eight months in middiaphyseal cross sections of femur from adult swine. Anat Rec 250:136-145.
35. Jefferson WN, Couse JF, Padilla-Benks E, Korech KS. 2002. Neonatal exposure to genistein induces estrogen receptor (ER) a expression and multioocyte follicles in maturing mouse ovary: Evidence for ERβ-mediated and nonestrogenic action. Biol Reprod 67:1285-1296.
36. Kido S, Inoue D, Hiura K, Javier W, Ito Y. 2003. Expression of RANK is dependent upon differentiation into macrophage/osteoclast lineage: induction by 1alpha,25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line. HL60. Bone 32:621-629.
37. Kimira M, Arai Y, Shimoi K, Watanabe S. 1998. Japanese intake of flavonoids and isoflavonoids from foods. J Epidemiol 8:168-175.
38. Kuiper GGJM, Lemmen JG, Carlsson BO, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson J-A. 1998. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139:4252-4263.
39. Kurzer MS. 2002. Hormonal effects of soy in premenopausal women and men. J Nutr 132:5705-5735.
40. LaCroix AZ. 2005. Estrogen with and without progestin: Benefits and risks of short-term use. Am J Med 118:79-87.
41. Lauderdale DS, Jacobsen SJ, Furner SE, Levy PS, Brody JA, Goldberg J. 1997. Hip fracture incidence among elderly Asian-American populations. Am J Epidemiol 146:502-509.
42. Lieberherr M, Cournot G, Robins SP. 2003. Guidelines for using in vitro models to study the effects of phytoestrogens on bone. Br J Nutr 89:S59-S73.
43. Martin PM, Horwitz KB, Ryan DS, McGuire WL. 1978. Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology 103:1860-1867.
44. Mei J, Yeung SSC, Kung AWC. 2001. High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal women, but not premenopausal women. J Clin Endocrinol Metab 86:5217-5221.
45. Merritt RJ, Jenks BH. 2004. Safety of soy-based infant formula containing isoflavones: The clinical evidence. J Nutr 134:1220S-1224S.
46. Miksicek RJ. 1995. Estrogenic flavonoids: Structural requirements for biological activity. Proc Soc Exp Biol Med 208:44-50.
47. Mimouni F, Campaigne B, Neylan M, Tsang RC. 1993. Bone mineralization in the first year of life in infants fed human milk, cow-milk formula, or soy-based formula. J Pediatr 122:348-354.
48. Mosekilde L, Weisbrode SE, Safron JA, Stills HF, Jankowsky ML, Ebert DC, Danielsen CC, Sogaard CH, Franks AF, Stevens ML, Paddock CL, Boyce RW. 1993. Evaluation of skeletal effects of combined mild dietary calcium restriction and ovariectomy in sinclair s-1 minipigs: A pilot study. J Bone Miner Res 8:1131-1321.
49. Murkies AL, Wilcox G, Davis SR. 1998. Clinical review 92: Phytoestrogens. J Clin Endocr Metab 83:297-303.
50. Nagel SC, vom Saal FS, Welshons WV. 1998. The effective free fraction of estradiol and xenoestrogens in human serum measured by whole cell uptake assays: Physiology of delivery modifies estrogenic activity. Proc Soc Exp Biol Med 217:300-309.
51. Nakai M, Cook L, Pyter LM, Black M, Sibona J, Turner RT, Jeffery EH, Bahr JM. 2005. Dietary soy protein and isoflavones have no significant effect on bone and potentially negative effect on the uterus of sexually mature intact Srague-Dawley female rats. Menopause 12:291-298.
52. Nikov GN, Hopkins NE, Boue S, Alworth WL. 2000. Interactions of dietary estrogens with human estrogen receptors and the effect on estrogen receptor-estrogen response element complex formation. Environ Health Perspect 108:847-872.
53. Owen TA, Aronow M, Shalhoub V, Barone LM, Wilming L, Tassinari MS, Kennedy MB, Pockwinse S, Lian JB, Stein GS. 1990. Progressive development of the rat osteoblast phenotype in vitro: Reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. J Cell Physiol 143:420-430.
54. Pelletier G, El-Alfy M. 2000. Immunocytochemical localisation of estrogen receptors α and β in the human reproductive organs. J Clin Endocrinol Metab 85:4835-4840.
55. Picherit C, Coxam V, Bennetau-Pelissero C, Kati-Coulibaly S, Davicco MJ, Lebecque P, Barlet JP. 2000. Daldzein is more effective than genistein in preventing ovariectomy-induced bone loss. J Nutr 130:1675-1681.
56. Picherit C, Chanteranne B, Bennetau-Pelissero C, Davicco MJ, Lebecque P, Barlet JP, Coxam V. 2001. Dose-dependant bone sparing effects of dietary Isoflavones in the ovariectomized rat. Brit J Nutr 85:307-316.
57. Pointillart A, Coxam V, Sėve B, Colin C, Lacroix CH, Guéguen L. 2000. Availability of calcium from skim milk, calcium sulfate and calcium carbonate for bone mineralization in pigs. Reprod Nutr Dev 40:49-61.
58. Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW, Jr. 1998. Soy protein and isoflavones: Their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 68:1375S-1379S.
59. Qi DY, Perkins SL, Kling SJ, Russell RGG. 1999. Divergent regulation of 1,25-dihydroxyvitamin D3 on human bone marrow osteoclastogenesis and myelopolesis. J Cell Biochem 72:387-395.
60. Rassi CM, Lieberherr M, Chaumaz G, Pointillart A, Coumot G. 2002. Down-regulation of osteoclast differentiation by daldzein via caspase 3. J Bone Miner Res 17:630-638.
61. Rassi CM, Lieberherr M, Chaumaz G, Pointillart A, Coumot G. 2005. Modulation of osteoclastogenesis in porcine bone marrow cultures by quercetin and rutin. Cell Tissue Res 319:383-393.
62. Ren MQ, Kuhn G, Wegner J, Nürmberg G, Chen J, Kender K. 2001. Feeding daldzein to late pregnant sows influences the estrogen receptor beta and type I insulin-growth factor receptor mRNA expression in newborn piglets. J Endocrinol 170:129-135.
63. Rickard DJ, Monroe DG, Ruesink TJ, Khosla S, Riggs BL, Spelsberg TC. 2003. Phytoestrogen genistein acts as an agonist on human osteoblastic cells through estrogen receptor α and α. J Cell Biochem 89:633-646.
64. Rizzoli R. 2006. Determinants of peak bona mass. Ann Endocrinol (Paris) 67:114-115.
65. Roodman GD. 1996. Advances in bone biology: The osteoclast. Endocr Rev 17:308-332.
66. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. 2006. Soy protein, isoflavones, and cardiovascular health: An American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 113:1034-1044.
67. Santeli RC, Chang YC, Nair MG, Helferich WG. 1997. Dietary genistein exerts estrogenic effects upon the uterus, mammary gland and the hypothalamic/pituitary axis in rats. J Nutr 127:263-269.
68. Sar M, Welsch F. 1999. Differential expression of estrogen receptor-β and receptor-α in the rat ovary. Endocrinology 140:463-971.
69. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. 2000. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485-491.
70. Scheven BAA, Milne JS, Robins SP. 1998. A sequential culture approach to study osteoclast differentiation from nonadherent porcine bone marrow cells. In Vitro Cell Dev Biol Anim 34:568-577.
71. Setcheli KDR, Casaldy A. 1999. Dietary isoflavones: Biological effects and relevance to human health. J Nutr 129:758S-767S.
72. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang M-S, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan H-L ,Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hugues TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R. Amgen EST Program, Boyle WJ. 1997. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
73. Slomczynska M, Wozniak J. 2001. Differential distribution of estrogen receptor-beta and estrogen receptor-alpha in the porcine ovary. Exp Clin Endocrinol Diabetes 109:238-244.
74. Spelsberg TC, Subramaniam M, Riggs BL, Khosla S. 1999. The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol Endocrinol 13:819-828.
75. Spencer TE, Wiley AA, Bartol FF. 1993. Neonatal age and period of estrogen exposure affect porcine uterine growth, morphogenesis, and protein synthesis. Biol Reprod 48:741-751.
76. Strom BL, Schinnar R, Ziegler EE, Barnhart KT, Sammel MD, Macones GA, Stallings VA, Drulis JM, Nelson SE, Hanson SA. 2001. Exposure to soy-based formula in infancy and endocrinological and reproductive outcomes in young adulthood. JAMA 286:807-814.
77. Suda T, Nakamura I, Jimi E, Takahashi N. 1997. Regulation of osteoclast function. J Bone Miner Res 12:869-879.
78. Sugimoto E, Yamaguchi M. 2000. Anabolic effect of daidzein in osteoblastic MC3T3-EI cells. Biochem Pharmacol 59:471-475.
79. Tarleton BJ, Wiley AA, Spencer TE, Moss AG, Bartol FF. 1998. Ovary-independent estrogen receptor expression in neonatal porcine endometrium. Biol Reprod 58:1009-1019.
80. Tham DM, Gardner CD, Haskell WL. 1998. Clinical review 97: Potential health benefits of dietary phytoestrogens: A review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocr Metab 83:2223-2235.
81. Thomson BM, Bennett J, Dean V, Triffitt J, Meikle MC, Loveridge N. 1993. Preliminary characterization of porcine bone marrow stromal cells: Skeletogenic potential, colony-forming activity and response to dexametasone, transforming growth factor β, and basic fibroblast growth factor. J Bone Miner Res 8:1173-1183.
82. Triffitt JT. 1996. The stem cell of osteoblast. In: Bilezikian PJ, Raisz LG, Rodan GA, Editors. Principles of Bone Biology. New-York: Academic Press. pp 39-50.
83. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T. 2000. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141:3478-3484.
84. Uehar M, Arai Y, Watanabe S, Aldercreutz H. 2000. Comparison of plasma and urinary phytoestrogens in Japanese and Finnish women by time-resolved fluoroimmunoassay. Biofactors 12:217-225.
85. Wada T, Nakashima T, Hiroshi N, Penninger JM. 2006. RANKL-RANK signaling in osteoclatogenesis and bone disease. Trends Mol Med 12:17-25.
86. Wang H, Tranguch S, Xie H, Hanley G, Das SK, Dey SK. 2005. Variation in commercial rodent diets induces disparate molecular and physiological changes in the mouse uterus. Proc Natl Acad Sci USA 102:9960-9965.
87. Wangen KE, Duncan AM, Merz-Demlow BE Xu X, Marcus RE, Phipps WR, Kurzer MS. 2000. Effects of soy isoflavones on markers of bone turnover in premenopausal and postmenopausal women. J On Endocrinol Metab 85:3043-3048.
88. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Knosaki M, Mochizukl S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclatogenesis-inhibitory factor and is identical to Trance/RANKL. Proc Natl Acad Sci USA 95:3597-3601